AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer
Update: 2025-05-07
Description
AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer
CME Available: https://auau.auanet.org/node/43069
At the conclusion of this CME activity, participants will be able to:
1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring.
2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.
3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.
4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.
5. Identify patients with radiorecurrent organ-confined prostate cancer.
ACKNOWLEDGEMENTS
Support provided by independent educational grants from:
Blue Earth Diagnostics, Inc.
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
CME Available: https://auau.auanet.org/node/43069
At the conclusion of this CME activity, participants will be able to:
1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring.
2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.
3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.
4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.
5. Identify patients with radiorecurrent organ-confined prostate cancer.
ACKNOWLEDGEMENTS
Support provided by independent educational grants from:
Blue Earth Diagnostics, Inc.
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
